News from IMIM
Galectin-1 (Gal1) inhibition may become the first effective treatment for slowing down the pancreatic ductal carcinoma progression, an incurable and most common type of pancreatic cancer. This study was conducted using a transgenic mouse model developed by the CNIO, which presents the mutation of the oncogen KRas, the most common mutation in pancreatic cancer. “This has allowed us to accurately recapitulate the tumor progression observed in humans” explained Pilar Navarro, one of the leaders of the project and researcher at IMIM and IIBB-CSIC.
This international research leaded by Pilar Navarro and Gabriel Rabinovich from the Institute of Experimental Biology and Medicine of Buenos Aires, has involved researchers from Spain (IMIM and CNIO), Argentina and USA, and was published in the journal Proceedings of the National Academy of Sciences. -CS/PRBB
Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk. Carlos A. Orozco, Neus Martinez-Bosch, Pedro E. Guerrero, Judith Vinaixa, Tomás Dalotto-Moreno, Mar Iglesias, Mireia Moreno, Magdolna Djurec, Françoise Poirier, Hans-Joachim Gabius, Martin E. Fernandez-Zapico, Rosa F. Hwang, Carmen Guerra, Gabriel A. Rabinovich and Pilar Navarro.PNAS April 3, 2018. 201722434; published ahead of print April 3, 2018.https://doi.org/10.1073/pnas.1722434115
IMIM website (In Spanish)